about
An appraisal of theoretical approaches to examining behaviours in relation to Human Papillomavirus (HPV) vaccination of young womenBarriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesisEffectiveness of meningococcal serogroup C conjugate vaccine 4 years after introductionInequalities in the uptake of human papillomavirus vaccination: a systematic review and meta-analysisEffect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].Implications of differential age distribution of disease-associated meningococcal lineages for vaccine development.Meningococcal carriage by age: a systematic review and meta-analysis.Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunityHousehold crowding, social mixing patterns and respiratory symptoms in seven countries of the African meningitis beltRe-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit.Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008Efficacy of pneumococcal vaccination in adults: a meta-analysis.Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013.The health, social and educational needs of children who have survived meningitis and septicaemia: the parents' perspectiveMethods for identifying Neisseria meningitidis carriers: a multi-center study in the African meningitis belt.Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis BeltSeroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introductionThe role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis BeltHigher Tetanus Toxoid Immunity 2 Years After PsA-TT Introduction in MaliMeningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina FasoCosts of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina FasoVaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysisA surveillance network for meningococcal disease in Europe.Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.Influenza and RSV make a modest contribution to invasive pneumococcal disease incidence in the UKPharyngeal carriage of Neisseria species in the African meningitis belt.Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.Increasing hospital admissions for pneumonia, EnglandMeningococcal carriage in the African meningitis belt.Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impactOptimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae.Barriers and facilitators to uptake of the school-based HPV vaccination programme in an ethnically diverse group of young womenSecular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004.Measuring Health Spillovers for Economic Evaluation: A Case Study in Meningitis.Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study.
P50
Q26796532-B506CD0D-D1E0-4C18-ABCA-4F16F583B4D1Q27027935-71E06162-E65F-43B0-B81F-4AC02B33229CQ28273949-67ECC49D-B35E-4ADE-B27D-74D5A7888A99Q28289664-DCC383FF-0DAB-424F-9416-CA42D9574C7CQ30566557-E80A2881-640A-49A5-82DB-CBA61073E231Q33743483-5C0582E1-7222-4DF9-932E-C8B3FC416B1EQ33746085-E43DBE21-A016-47C3-B60C-41141AB22C46Q33825722-5503A937-AF75-440D-B55E-395FAE29421EQ33837062-7DD0D5BB-FF0F-4E43-A319-F76FE7EC003CQ34316082-E4CA3770-658D-4C8F-AE45-CD4313F76ECAQ34537851-704B9706-A18E-4B10-A301-DC2A4703547BQ34606343-4B48D72B-1540-4175-B9E4-0F86F9F88A8EQ34657877-A24D5C7F-09B6-4C8F-9AB5-8116D04AE9C7Q34844225-2FC2D0DF-15BB-4DF8-856E-01DC41F609B7Q35013440-532D029D-4952-4AE0-BB61-FD0CF3392FD9Q35032544-E0940C06-2ADC-4B8C-B262-0252AB714903Q35739057-F6B23EEE-07AD-4C12-8A8F-34A27C678724Q35922578-16BA692B-5049-4C9C-8AE3-68F36739D3F4Q35946870-1113AAB5-F331-414E-8A8B-57FA47BD37CFQ36154716-8BC2F249-EF07-4903-AEFB-808C8F97B597Q36253528-1894A4C1-ACCE-48F1-92F4-29A2E5E7BCDFQ36265017-290F9696-89EE-4B90-90BB-BFE04B6080EFQ36265027-2EF0D978-465D-4D88-84DB-CAD26F954DCAQ36265037-A5DFCE5A-1BB6-4793-9697-97799AC560E5Q36265070-CE3319CE-8685-4E2D-87AE-A7DD70BC45C2Q36350368-24E1C96A-047B-4ADC-B819-902DCA9D8D19Q36683965-100391F1-466D-4D8C-B4A5-0AF3D95912E9Q36683979-BEE74E13-57C6-48A5-B561-EC387281E156Q36833186-141619F1-7944-4576-A868-EC73D9388FB7Q36934747-2184C0FC-5701-4CE0-BFFB-A39EFC262483Q36974336-ECFB0817-7D87-493A-BECF-874DAC3BE393Q37009138-E764CF83-8843-43F7-8BA0-B8D8CD303121Q37018218-E066ABF9-363B-498C-8893-EAE028577A30Q37094305-85A97E45-E403-432A-8100-B0568DFC6E2FQ37212564-B24B51B9-AFFE-4193-BE10-C53E627A9F25Q37353417-7DD6C23E-EA48-4F43-9F5E-E836245B48FEQ37396566-EA35A5ED-FAE3-48B3-ADBB-7A8FBC60DEF9Q37417666-5D04AF4D-0C58-415E-9E6E-6104366A02C1Q37524027-C45972AA-348B-4185-BF22-C6D7EAB2A075Q37525000-BDB2B50C-F8B4-4C94-83F5-A44BF06B484A
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Caroline Trotter
@ast
Caroline Trotter
@en
Caroline Trotter
@es
Caroline Trotter
@nl
Caroline Trotter
@sl
type
label
Caroline Trotter
@ast
Caroline Trotter
@en
Caroline Trotter
@es
Caroline Trotter
@nl
Caroline Trotter
@sl
prefLabel
Caroline Trotter
@ast
Caroline Trotter
@en
Caroline Trotter
@es
Caroline Trotter
@nl
Caroline Trotter
@sl
P106
P1153
7005753490
P21
P31
P496
0000-0003-4000-2708